Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Open Access
- 27 April 2012
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 79
Abstract
The potent ribonucleotide reductase (RNR) inhibitor 3-aminopyridine-2-carboxyaldehyde-thiosemicarbazone (3-AP) was tested as a chemosensitizer for restored cisplatin-mediated cytotoxicity in platinum-resistant ovarian cancer.Keywords
This publication has 34 references indexed in Scilit:
- Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical CancersRadiation Research, 2010
- A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancerCancer Chemotherapy and Pharmacology, 2004
- Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous InfusionJournal of Clinical Oncology, 2004
- Phosphorylation of histone H2AX as a measure of radiosensitivityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Cisplatin, Doxorubicin and Paclitaxel Induce mdr1 Gene Transcription in Ovarian Cancer Cell Lines2003
- Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.2003
- Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose scheduleCancer Chemotherapy and Pharmacology, 2002
- Controlled Protein Degradation Regulates Ribonucleotide Reductase Activity in Proliferating Mammalian Cells during the Normal Cell Cycle and in Response to DNA Damage and Replication BlocksJournal of Biological Chemistry, 2000